Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ffba028b677-trace').style.display = (document.getElementById('cakeErr67ffba028b677-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ffba028b677-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ffba028b677-code').style.display = (document.getElementById('cakeErr67ffba028b677-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ffba028b677-context').style.display = (document.getElementById('cakeErr67ffba028b677-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ffba028b677-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ffba028b677-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27162,
		&#039;title&#039; =&gt; &#039;More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Mumbai: &lt;/em&gt;A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Earlier last month, the Patent office had rejected California-based Gilead&#039;s patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office&#039;s order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sankalp&#039;s opposition is the fourth opposition against Gilead&#039;s base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We have studied the patent application closely and are convinced that it has no merit&amp;quot; Anand Grover, Director, Lawyers Collective, said in a statement. &amp;quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India&#039;s patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&amp;quot; he added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Oral pill&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Further, the pro-health group opposing Gilead&#039;s patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&amp;quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It is unfortunate that generic companies in India, who once played David to MNC&#039;s Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&amp;quot; added Grover, referring to earlier groundbreaking patent-battles in the country.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 2 February, 2015, http://www.thehindubusinessline.com/companies/more-patentopposition-on-gileads-hepatitis-c-drug-sofosbuvir/article6847904.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675210,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27162,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic medicine,generic medicines,Access to Health,Access to Healthcare,Patented Medicines,Hepatitis C,Access to Medicines,medicines,Public Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu Business Line


Mumbai: A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.


Non-government organisation Sankalp Rehabilitation...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Mumbai: &lt;/em&gt;A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Earlier last month, the Patent office had rejected California-based Gilead&#039;s patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office&#039;s order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sankalp&#039;s opposition is the fourth opposition against Gilead&#039;s base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We have studied the patent application closely and are convinced that it has no merit&amp;quot; Anand Grover, Director, Lawyers Collective, said in a statement. &amp;quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India&#039;s patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&amp;quot; he added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Oral pill&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Further, the pro-health group opposing Gilead&#039;s patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&amp;quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It is unfortunate that generic companies in India, who once played David to MNC&#039;s Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&amp;quot; added Grover, referring to earlier groundbreaking patent-battles in the country.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27162,
	&#039;title&#039; =&gt; &#039;More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Mumbai: &lt;/em&gt;A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Earlier last month, the Patent office had rejected California-based Gilead&#039;s patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office&#039;s order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sankalp&#039;s opposition is the fourth opposition against Gilead&#039;s base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We have studied the patent application closely and are convinced that it has no merit&amp;quot; Anand Grover, Director, Lawyers Collective, said in a statement. &amp;quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India&#039;s patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&amp;quot; he added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Oral pill&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Further, the pro-health group opposing Gilead&#039;s patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&amp;quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It is unfortunate that generic companies in India, who once played David to MNC&#039;s Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&amp;quot; added Grover, referring to earlier groundbreaking patent-battles in the country.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 2 February, 2015, http://www.thehindubusinessline.com/companies/more-patentopposition-on-gileads-hepatitis-c-drug-sofosbuvir/article6847904.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675210,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27162
$metaTitle = &#039;LATEST NEWS UPDATES | More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta&#039;
$metaKeywords = &#039;generic medicine,generic medicines,Access to Health,Access to Healthcare,Patented Medicines,Hepatitis C,Access to Medicines,medicines,Public Health&#039;
$metaDesc = &#039;
-The Hindu Business Line


Mumbai: A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.


Non-government organisation Sankalp Rehabilitation...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Mumbai: &lt;/em&gt;A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Earlier last month, the Patent office had rejected California-based Gilead&#039;s patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office&#039;s order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sankalp&#039;s opposition is the fourth opposition against Gilead&#039;s base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We have studied the patent application closely and are convinced that it has no merit&amp;quot; Anand Grover, Director, Lawyers Collective, said in a statement. &amp;quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India&#039;s patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&amp;quot; he added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Oral pill&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Further, the pro-health group opposing Gilead&#039;s patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&amp;quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It is unfortunate that generic companies in India, who once played David to MNC&#039;s Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&amp;quot; added Grover, referring to earlier groundbreaking patent-battles in the country.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta | Im4change.org</title>
    <meta name="description" content="
-The Hindu Business Line


Mumbai: A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.


Non-government organisation Sankalp Rehabilitation..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu Business Line</div><p align="justify"><em>Mumbai: </em>A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.</p><p align="justify">Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)</p><p align="justify">Earlier last month, the Patent office had rejected California-based Gilead's patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office's order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.</p><p align="justify">Sankalp's opposition is the fourth opposition against Gilead's base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.</p><p align="justify">Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.</p><p align="justify">&quot;We have studied the patent application closely and are convinced that it has no merit&quot; Anand Grover, Director, Lawyers Collective, said in a statement. &quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India's patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&quot; he added.</p><p align="justify">The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.</p><p align="justify">Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.</p><p align="justify">Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.</p><p align="justify"><em>Oral pill</em></p><p align="justify">Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.</p><p align="justify">Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.</p><p align="justify">Further, the pro-health group opposing Gilead's patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.</p><p align="justify">&quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.</p><p align="justify">&quot;It is unfortunate that generic companies in India, who once played David to MNC's Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&quot; added Grover, referring to earlier groundbreaking patent-battles in the country.</p><p align="justify">&nbsp;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ffba028b677-trace').style.display = (document.getElementById('cakeErr67ffba028b677-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ffba028b677-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ffba028b677-code').style.display = (document.getElementById('cakeErr67ffba028b677-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ffba028b677-context').style.display = (document.getElementById('cakeErr67ffba028b677-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ffba028b677-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ffba028b677-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27162,
		&#039;title&#039; =&gt; &#039;More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Mumbai: &lt;/em&gt;A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Earlier last month, the Patent office had rejected California-based Gilead&#039;s patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office&#039;s order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sankalp&#039;s opposition is the fourth opposition against Gilead&#039;s base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We have studied the patent application closely and are convinced that it has no merit&amp;quot; Anand Grover, Director, Lawyers Collective, said in a statement. &amp;quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India&#039;s patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&amp;quot; he added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Oral pill&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Further, the pro-health group opposing Gilead&#039;s patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&amp;quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It is unfortunate that generic companies in India, who once played David to MNC&#039;s Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&amp;quot; added Grover, referring to earlier groundbreaking patent-battles in the country.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 2 February, 2015, http://www.thehindubusinessline.com/companies/more-patentopposition-on-gileads-hepatitis-c-drug-sofosbuvir/article6847904.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675210,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27162,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic medicine,generic medicines,Access to Health,Access to Healthcare,Patented Medicines,Hepatitis C,Access to Medicines,medicines,Public Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu Business Line


Mumbai: A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.


Non-government organisation Sankalp Rehabilitation...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Mumbai: &lt;/em&gt;A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Earlier last month, the Patent office had rejected California-based Gilead&#039;s patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office&#039;s order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sankalp&#039;s opposition is the fourth opposition against Gilead&#039;s base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We have studied the patent application closely and are convinced that it has no merit&amp;quot; Anand Grover, Director, Lawyers Collective, said in a statement. &amp;quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India&#039;s patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&amp;quot; he added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Oral pill&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Further, the pro-health group opposing Gilead&#039;s patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&amp;quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It is unfortunate that generic companies in India, who once played David to MNC&#039;s Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&amp;quot; added Grover, referring to earlier groundbreaking patent-battles in the country.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27162,
	&#039;title&#039; =&gt; &#039;More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Mumbai: &lt;/em&gt;A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Earlier last month, the Patent office had rejected California-based Gilead&#039;s patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office&#039;s order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sankalp&#039;s opposition is the fourth opposition against Gilead&#039;s base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We have studied the patent application closely and are convinced that it has no merit&amp;quot; Anand Grover, Director, Lawyers Collective, said in a statement. &amp;quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India&#039;s patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&amp;quot; he added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Oral pill&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Further, the pro-health group opposing Gilead&#039;s patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&amp;quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It is unfortunate that generic companies in India, who once played David to MNC&#039;s Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&amp;quot; added Grover, referring to earlier groundbreaking patent-battles in the country.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 2 February, 2015, http://www.thehindubusinessline.com/companies/more-patentopposition-on-gileads-hepatitis-c-drug-sofosbuvir/article6847904.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675210,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27162
$metaTitle = &#039;LATEST NEWS UPDATES | More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta&#039;
$metaKeywords = &#039;generic medicine,generic medicines,Access to Health,Access to Healthcare,Patented Medicines,Hepatitis C,Access to Medicines,medicines,Public Health&#039;
$metaDesc = &#039;
-The Hindu Business Line


Mumbai: A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.


Non-government organisation Sankalp Rehabilitation...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Mumbai: &lt;/em&gt;A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Earlier last month, the Patent office had rejected California-based Gilead&#039;s patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office&#039;s order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sankalp&#039;s opposition is the fourth opposition against Gilead&#039;s base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We have studied the patent application closely and are convinced that it has no merit&amp;quot; Anand Grover, Director, Lawyers Collective, said in a statement. &amp;quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India&#039;s patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&amp;quot; he added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Oral pill&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Further, the pro-health group opposing Gilead&#039;s patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&amp;quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It is unfortunate that generic companies in India, who once played David to MNC&#039;s Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&amp;quot; added Grover, referring to earlier groundbreaking patent-battles in the country.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta | Im4change.org</title>
    <meta name="description" content="
-The Hindu Business Line


Mumbai: A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.


Non-government organisation Sankalp Rehabilitation..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu Business Line</div><p align="justify"><em>Mumbai: </em>A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.</p><p align="justify">Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)</p><p align="justify">Earlier last month, the Patent office had rejected California-based Gilead's patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office's order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.</p><p align="justify">Sankalp's opposition is the fourth opposition against Gilead's base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.</p><p align="justify">Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.</p><p align="justify">&quot;We have studied the patent application closely and are convinced that it has no merit&quot; Anand Grover, Director, Lawyers Collective, said in a statement. &quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India's patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&quot; he added.</p><p align="justify">The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.</p><p align="justify">Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.</p><p align="justify">Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.</p><p align="justify"><em>Oral pill</em></p><p align="justify">Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.</p><p align="justify">Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.</p><p align="justify">Further, the pro-health group opposing Gilead's patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.</p><p align="justify">&quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.</p><p align="justify">&quot;It is unfortunate that generic companies in India, who once played David to MNC's Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&quot; added Grover, referring to earlier groundbreaking patent-battles in the country.</p><p align="justify">&nbsp;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ffba028b677-trace').style.display = (document.getElementById('cakeErr67ffba028b677-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67ffba028b677-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ffba028b677-code').style.display = (document.getElementById('cakeErr67ffba028b677-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67ffba028b677-context').style.display = (document.getElementById('cakeErr67ffba028b677-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67ffba028b677-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67ffba028b677-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27162,
		&#039;title&#039; =&gt; &#039;More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Mumbai: &lt;/em&gt;A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Earlier last month, the Patent office had rejected California-based Gilead&#039;s patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office&#039;s order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sankalp&#039;s opposition is the fourth opposition against Gilead&#039;s base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We have studied the patent application closely and are convinced that it has no merit&amp;quot; Anand Grover, Director, Lawyers Collective, said in a statement. &amp;quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India&#039;s patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&amp;quot; he added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Oral pill&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Further, the pro-health group opposing Gilead&#039;s patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&amp;quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It is unfortunate that generic companies in India, who once played David to MNC&#039;s Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&amp;quot; added Grover, referring to earlier groundbreaking patent-battles in the country.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 2 February, 2015, http://www.thehindubusinessline.com/companies/more-patentopposition-on-gileads-hepatitis-c-drug-sofosbuvir/article6847904.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675210,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27162,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;generic medicine,generic medicines,Access to Health,Access to Healthcare,Patented Medicines,Hepatitis C,Access to Medicines,medicines,Public Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu Business Line


Mumbai: A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.


Non-government organisation Sankalp Rehabilitation...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Mumbai: &lt;/em&gt;A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Earlier last month, the Patent office had rejected California-based Gilead&#039;s patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office&#039;s order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sankalp&#039;s opposition is the fourth opposition against Gilead&#039;s base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We have studied the patent application closely and are convinced that it has no merit&amp;quot; Anand Grover, Director, Lawyers Collective, said in a statement. &amp;quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India&#039;s patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&amp;quot; he added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Oral pill&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Further, the pro-health group opposing Gilead&#039;s patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&amp;quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It is unfortunate that generic companies in India, who once played David to MNC&#039;s Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&amp;quot; added Grover, referring to earlier groundbreaking patent-battles in the country.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27162,
	&#039;title&#039; =&gt; &#039;More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu Business Line
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Mumbai: &lt;/em&gt;A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Earlier last month, the Patent office had rejected California-based Gilead&#039;s patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office&#039;s order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sankalp&#039;s opposition is the fourth opposition against Gilead&#039;s base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We have studied the patent application closely and are convinced that it has no merit&amp;quot; Anand Grover, Director, Lawyers Collective, said in a statement. &amp;quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India&#039;s patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&amp;quot; he added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Oral pill&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Further, the pro-health group opposing Gilead&#039;s patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&amp;quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;It is unfortunate that generic companies in India, who once played David to MNC&#039;s Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&amp;quot; added Grover, referring to earlier groundbreaking patent-battles in the country.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu Business Line, 2 February, 2015, http://www.thehindubusinessline.com/companies/more-patentopposition-on-gileads-hepatitis-c-drug-sofosbuvir/article6847904.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675210,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27162
$metaTitle = &#039;LATEST NEWS UPDATES | More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta&#039;
$metaKeywords = &#039;generic medicine,generic medicines,Access to Health,Access to Healthcare,Patented Medicines,Hepatitis C,Access to Medicines,medicines,Public Health&#039;
$metaDesc = &#039;
-The Hindu Business Line


Mumbai: A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.


Non-government organisation Sankalp Rehabilitation...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu Business Line&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Mumbai: &lt;/em&gt;A fresh bout of opposition has been filed against Gilead&#039;s patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Earlier last month, the Patent office had rejected California-based Gilead&#039;s patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office&#039;s order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sankalp&#039;s opposition is the fourth opposition against Gilead&#039;s base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We have studied the patent application closely and are convinced that it has no merit&amp;quot; Anand Grover, Director, Lawyers Collective, said in a statement. &amp;quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India&#039;s patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&amp;quot; he added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Oral pill&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Further, the pro-health group opposing Gilead&#039;s patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&amp;quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;It is unfortunate that generic companies in India, who once played David to MNC&#039;s Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&amp;quot; added Grover, referring to earlier groundbreaking patent-battles in the country.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta | Im4change.org</title>
    <meta name="description" content="
-The Hindu Business Line


Mumbai: A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.


Non-government organisation Sankalp Rehabilitation..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu Business Line</div><p align="justify"><em>Mumbai: </em>A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.</p><p align="justify">Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)</p><p align="justify">Earlier last month, the Patent office had rejected California-based Gilead's patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office's order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.</p><p align="justify">Sankalp's opposition is the fourth opposition against Gilead's base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.</p><p align="justify">Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.</p><p align="justify">&quot;We have studied the patent application closely and are convinced that it has no merit&quot; Anand Grover, Director, Lawyers Collective, said in a statement. &quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India's patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&quot; he added.</p><p align="justify">The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.</p><p align="justify">Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.</p><p align="justify">Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.</p><p align="justify"><em>Oral pill</em></p><p align="justify">Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.</p><p align="justify">Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.</p><p align="justify">Further, the pro-health group opposing Gilead's patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.</p><p align="justify">&quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.</p><p align="justify">&quot;It is unfortunate that generic companies in India, who once played David to MNC's Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&quot; added Grover, referring to earlier groundbreaking patent-battles in the country.</p><p align="justify">&nbsp;</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 27162,
		'title' => 'More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta',
		'subheading' => '',
		'description' => '<div align="justify">
-The Hindu Business Line
</div>
<p align="justify">
<em>Mumbai: </em>A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.
</p>
<p align="justify">
Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)
</p>
<p align="justify">
Earlier last month, the Patent office had rejected California-based Gilead's patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office's order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.
</p>
<p align="justify">
Sankalp's opposition is the fourth opposition against Gilead's base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.
</p>
<p align="justify">
Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.
</p>
<p align="justify">
&quot;We have studied the patent application closely and are convinced that it has no merit&quot; Anand Grover, Director, Lawyers Collective, said in a statement. &quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India's patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&quot; he added.
</p>
<p align="justify">
The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.
</p>
<p align="justify">
Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.
</p>
<p align="justify">
Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.
</p>
<p align="justify">
<em>Oral pill</em>
</p>
<p align="justify">
Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.
</p>
<p align="justify">
Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.
</p>
<p align="justify">
Further, the pro-health group opposing Gilead's patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.
</p>
<p align="justify">
&quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.
</p>
<p align="justify">
&quot;It is unfortunate that generic companies in India, who once played David to MNC's Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&quot; added Grover, referring to earlier groundbreaking patent-battles in the country.
</p>
<p align="justify">
&nbsp;
</p>',
		'credit_writer' => 'The Hindu Business Line, 2 February, 2015, http://www.thehindubusinessline.com/companies/more-patentopposition-on-gileads-hepatitis-c-drug-sofosbuvir/article6847904.ece',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4675210,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 27162,
	'metaTitle' => 'LATEST NEWS UPDATES | More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta',
	'metaKeywords' => 'generic medicine,generic medicines,Access to Health,Access to Healthcare,Patented Medicines,Hepatitis C,Access to Medicines,medicines,Public Health',
	'metaDesc' => '
-The Hindu Business Line


Mumbai: A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.


Non-government organisation Sankalp Rehabilitation...',
	'disp' => '<div align="justify">-The Hindu Business Line</div><p align="justify"><em>Mumbai: </em>A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.</p><p align="justify">Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)</p><p align="justify">Earlier last month, the Patent office had rejected California-based Gilead's patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office's order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.</p><p align="justify">Sankalp's opposition is the fourth opposition against Gilead's base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.</p><p align="justify">Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.</p><p align="justify">&quot;We have studied the patent application closely and are convinced that it has no merit&quot; Anand Grover, Director, Lawyers Collective, said in a statement. &quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India's patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&quot; he added.</p><p align="justify">The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.</p><p align="justify">Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.</p><p align="justify">Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.</p><p align="justify"><em>Oral pill</em></p><p align="justify">Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.</p><p align="justify">Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.</p><p align="justify">Further, the pro-health group opposing Gilead's patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.</p><p align="justify">&quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.</p><p align="justify">&quot;It is unfortunate that generic companies in India, who once played David to MNC's Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&quot; added Grover, referring to earlier groundbreaking patent-battles in the country.</p><p align="justify">&nbsp;</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 27162,
	'title' => 'More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta',
	'subheading' => '',
	'description' => '<div align="justify">
-The Hindu Business Line
</div>
<p align="justify">
<em>Mumbai: </em>A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.
</p>
<p align="justify">
Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)
</p>
<p align="justify">
Earlier last month, the Patent office had rejected California-based Gilead's patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office's order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.
</p>
<p align="justify">
Sankalp's opposition is the fourth opposition against Gilead's base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.
</p>
<p align="justify">
Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.
</p>
<p align="justify">
&quot;We have studied the patent application closely and are convinced that it has no merit&quot; Anand Grover, Director, Lawyers Collective, said in a statement. &quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India's patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&quot; he added.
</p>
<p align="justify">
The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.
</p>
<p align="justify">
Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.
</p>
<p align="justify">
Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.
</p>
<p align="justify">
<em>Oral pill</em>
</p>
<p align="justify">
Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.
</p>
<p align="justify">
Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.
</p>
<p align="justify">
Further, the pro-health group opposing Gilead's patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.
</p>
<p align="justify">
&quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.
</p>
<p align="justify">
&quot;It is unfortunate that generic companies in India, who once played David to MNC's Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&quot; added Grover, referring to earlier groundbreaking patent-battles in the country.
</p>
<p align="justify">
&nbsp;
</p>',
	'credit_writer' => 'The Hindu Business Line, 2 February, 2015, http://www.thehindubusinessline.com/companies/more-patentopposition-on-gileads-hepatitis-c-drug-sofosbuvir/article6847904.ece',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'more-patent-opposition-on-gileads-hepatitis-c-drug-sofosbuvir-pt-jyothi-datta-4675210',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4675210,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {},
		(int) 7 => object(Cake\ORM\Entity) {},
		(int) 8 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 27162
$metaTitle = 'LATEST NEWS UPDATES | More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta'
$metaKeywords = 'generic medicine,generic medicines,Access to Health,Access to Healthcare,Patented Medicines,Hepatitis C,Access to Medicines,medicines,Public Health'
$metaDesc = '
-The Hindu Business Line


Mumbai: A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.


Non-government organisation Sankalp Rehabilitation...'
$disp = '<div align="justify">-The Hindu Business Line</div><p align="justify"><em>Mumbai: </em>A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month.</p><p align="justify">Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.)</p><p align="justify">Earlier last month, the Patent office had rejected California-based Gilead's patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office's order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said.</p><p align="justify">Sankalp's opposition is the fourth opposition against Gilead's base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited.</p><p align="justify">Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office.</p><p align="justify">&quot;We have studied the patent application closely and are convinced that it has no merit&quot; Anand Grover, Director, Lawyers Collective, said in a statement. &quot;It fails to satisfy any grounds required to meet the threshold of what is patentable under India's patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)&quot; he added.</p><p align="justify">The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April.</p><p align="justify">Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets.</p><p align="justify">Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period.</p><p align="justify"><em>Oral pill</em></p><p align="justify">Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said.</p><p align="justify">Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added.</p><p align="justify">Further, the pro-health group opposing Gilead's patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment.</p><p align="justify">&quot;We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions,&quot; Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement.</p><p align="justify">&quot;It is unfortunate that generic companies in India, who once played David to MNC's Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines&quot; added Grover, referring to earlier groundbreaking patent-battles in the country.</p><p align="justify">&nbsp;</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

More patent-opposition on Gilead’s hepatitis C drug, sofosbuvir -PT Jyothi Datta

-The Hindu Business Line Mumbai: A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month. Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application before the Patent office decides on whether or not to grant the drug a patent.) Earlier last month, the Patent office had rejected California-based Gilead's patent application on the drug, on the grounds that it did not exhibit greater efficacy. Gilead had subsequently approached the Delhi High Court on this order. And later in the month, the Delhi High Court set aside the patent office's order that rejected the application, in effect returning proceedings for a fresh round of hearings on the sofosbuvir patent application, a lawyer familiar with the case said. Sankalp's opposition is the fourth opposition against Gilead's base patent application. Others include oppositions by I-Mak together with the Delhi Network of Positive People, Natco Pharma and BDR Pharmaceuticals International Limited. Gilead was not immediately reachable for comment on the latest development. In fact, it has another patent application on the drug that is now pending at the Kolkata patent office. "We have studied the patent application closely and are convinced that it has no merit" Anand Grover, Director, Lawyers Collective, said in a statement. "It fails to satisfy any grounds required to meet the threshold of what is patentable under India's patent law. Not only is it not new or inventive, it also does not comply with the requirements of Section 3 (d)" he added. The latest development comes even as Gilead received regulatory approval in India to market its version of the drug. It is expected to be launched around April. Last year, Gilead also inked alliances with eight India-based drug companies, allowing them to make generic, less expensive versions of the drug for certain markets. Gilead has been facing the heat on its otherwise breakthrough drug for its pricing. The drug is priced at $ 84,000 for 12 weeks and is expected to come to India at about $ 900 for the same period. Oral pill Sofosbuvir is a once-a-day oral pill that can change the treatment landscape for patients. It is reported to have cure rates of upto 95 per cent compared to 65-70 per cent witnessed with weekly-injections of Pegylated Interferon, the standard current treatment, a note said. Globally, there are around 180 million people living with hepatitis C of whom 12 million live in India, it added. Further, the pro-health group opposing Gilead's patent on sofosbuvir pointed out, under the licenses generic sofosbuvir could cost anywhere between $300 and $900 per treatment. "We know that even $300 is too expensive for the average person in India, let alone the poor. Open, unrestricted competition by Indian generic companies was responsible for drastic price reductions in ARV (anti-retroviral or anti-AIDSdrugs) prices which allowed scaling-up of treatment to millions," Eldred Tellis, Director, Sankalp Rehabilitation Trust, said in a statement. "It is unfortunate that generic companies in India, who once played David to MNC's Goliath have now chosen to go down this road. As civil society, we will continue to use pro-public health provisions to further access to medicines" added Grover, referring to earlier groundbreaking patent-battles in the country.